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A B S T R A C T
Introduction: Radiotherapy treatment planning is a multi-criteria problem. Any optimization of the process
produces a set of mathematically optimal solutions. These optimal plans are considered mathematically equal,
but they differ in terms of the trade-offs involved. Since the various objectives are conflicting, the choice of the
best plan for treatment is dependent on the preferences of the radiation oncologists or the medical physicists
(decision makers).
We defined a clinically relevant area on a prostate Pareto front which better represented clinical preferences
and determined if there were differences among radiation oncologists and medical physicists.
Methods and materials: Pareto fronts of five localized prostate cancer patients were used to analyze and visualize
the trade-off between the rectum sparing and the PTV under-dosage. Clinical preferences were evaluated with
Clinical Grading Analysis by asking nine radiation oncologists and ten medical physicists to rate pairs of plans
presented side by side. A choice of the optimal plan on the Pareto front was made by all decision makers.
Results: The plans in the central region of the Pareto front (1–4% PTV under-dosage) received the best eva-
luations. Radiation oncologists preferred the organ at risk (OAR) sparing region (2.5–4% PTV under-dosage)
while medical physicists preferred better PTV coverage (1–2.5% PTV under-dosage). When the Pareto fronts
were additionally presented to the decisions makers they systematically chose the plan in the trade-off region
(0.5–1% PTV under-dosage).
Conclusion: We determined a specific region on the Pareto front preferred by the radiation oncologists and
medical physicists and found a difference between them.
1. Introduction
In radiation therapy, the conventional treatment planning optimi-
zation process is a trial and error loop that leads to a single plan. Most
optimization systems need a set of goals formulated as dose-volume
objectives, each assigned with a ‘weight’ or ‘importance’. The choice of
appropriate objective weights is not obvious to the planner as they are
not directly related to a clinical objective [1]. Furthermore, the quality
of the entire 3D dose distribution is assessed through a single cost
function value that combines all the objectives used to formulate the
treatment planning problem [2].
Another approach used to attain a high-quality treatment plan is
auto-planning (see [3;4] for extensive reviews). In this system, the plan
is created from a database where previous plans are stored. The new
plan is obtained from cases stored in the database, usually by “opti-
mization” of dose volume histogram (DVH) data. This method has
demonstrated that it improves upon the final plan compared to the
manual technique of conventional optimization methods. Note, how-
ever, that the goal motivating this technique is not to obtain an optimal
plan but to automatize the treatment planning process [5–7].
At the end of the optimization run, either with the manual optimi-
zation method or with auto-planning, the decision maker – a radiation
oncologist (RO) or medical physicist (MP) – is not given information to
conclude whether a more clinically optimal solution could be reached.
Due to the long optimization process, the decision maker usually
evaluates one or a few available solutions out of the entire continuum of
possible plans that constitute the solution space and often selects among
mathematically and clinically sub-optimal solutions [8]. These limita-
tions compromise the possibility of fully exploring the trade-offs and
available dosimetric options for each patient.
A clear representation of the solution space and the ranges of the
trade-offs involved could lead to more informed clinical decision
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making and better treatment plans [8–11]. Multi-objective optimization
problems generally do not have a unique solution that can satisfy all
objectives simultaneously, but rather a set of Pareto optimal solutions,
which dominate all other non-optimal solutions. Additionally, each
plan on the Pareto front is Pareto optimal, ensuring that a mathema-
tically optimal solution is attained.
The process of evaluating and making decisions regarding radiation
dose compromises within the treatment plan that will be delivered in-
cludes judgment tasks for the trade-offs involved. Since the planning
criteria are usually conflicting, the decision largely depends on the
preferences of the decision maker. Given that the decision maker makes
a decision after a holistic assessment of the plan, it is important to have
information about the relevant ranges of the evaluation parameters and
their interdependencies. However, current treatment planning techni-
ques rarely provide this information. In this context, the Pareto front
concept has been proposed as an appropriate tool for the comparison of
treatment plans [12].
In this study we explored the clinical preferences of the decision
makers among plans on the Pareto front. The evaluation was performed
using Clinical Grading Analysis (CGA), a method similar to the visual
grading analysis used in radiology [13]. It identifies clinically relevant
differences between the plans instead of comparing them in an abolute
sense. A grading scale is defined in order to classify the relative quality
of one plan compared to another (e.g. « much better », or « equiva-
lent »). Our aim was to investigate the possibility of defining a clinically
relevant area on the Pareto front. Additionally, we determined if there
were differences in the plan choices between the two groups of spe-
cialists (radiation oncologists and medical physicists) involved in the
process of approving a treatment plan. Our intention was to illustrate
an effective method to gain insight about clinical choices using the
concept of the Pareto front.
2. Materials and methods
2.1. Patient selection and treatment planning data
We randomly selected five localized prostate cancer cases from the
patient database of our center. The study was exempt from further
ethics committee approval because the data were anonymized and the
results had no impact on the treatment outcome of the patients. Indeed,
the number of patients was limited. This choice was done due to the
time-consuming process of creating manual Pareto fronts. It was not the
aim of the study to provide a universal solution to the question of
clinical preference among plans on the Pareto front.
The organs delineated were the Clinical Target Volume (CTV), the
Planning Target Volume (PTV), bladder, rectum (defined as the entire
volume) and femoral heads. The plans were made according to the
RTOG 0415 protocol. Additional information can be found in
Supplementary Materials. The rectum was delineated from the recto-
sigmoid flexure to the anal canal. The ratio of the overlapped volume of
the PTV and the rectum volume to the rectum volume was 13%, 25%,
11%, 10%, and 4% for each plan, respectively. We used the To-
motherapy (Accuray, CA, USA) treatment planning system V5.0 to
optimize all the plans in the study that were calculated to be potentially
delivered on a Tomotherapy HD device. In all five clinical cases the
prescription dose was 78 Gy to the PTV.
We created Pareto fronts of the rectum sparing vs. PTV coverage
trade-off for all the cases, based on two clinical evaluation criteria
(Figure S1 in Supplementary Materials). Rectum sparing was evaluated
through the D50% objective, where D50% is the median dose to the
rectum. PTV coverage was evaluated through the V95% objective, where
V95% is the percent volume receiving at least 95% of the prescription
dose. We focused on this single trade-off in order to simplify the opti-
mization problem and reduce its multi-dimensionality when involving
the other organs at risk (OAR). The different plans constituting the
Pareto front concerning a specific trade-off were obtained by gradually
increasing the penalty values for the rectum objective while keeping the
values of all the other parameters of all OARs constant, and the opti-
mization was continued. It was practically impossible to strictly control
all the parameters of all the structures involved at the same time.
We achieved the best we could by keeping the values of all other
parameters of all OARs constant while allowing for dose deviations of
1 Gy maximum on average.
2.2. Clinical grading analysis
The trade-off was explored through a sequence of paired choice
tasks. In this study the plans under evaluation involved a non-Pareto
optimal plan with 0% PTV under-dosage (Plan 0_0), and optimal plans
on the Pareto front with 0% (Plan 0), 1% (Plan 1), 2.5% (Plan 2.5), 4%
(Plan 4) and 5% (Plan 5) PTV under-dosage (Figure S2 in
Supplementary Materials). All the possible pairs of plans were pre-
sented for comparison. Nineteen decision makers (nine radiation on-
cologists and ten medical physicists) from four different radiation
therapy centers evaluated the quality of the plans. We chose to ask
decision makers from more than one center to avoid any possible bias
that might occur due to a single center evaluation. The decision makers
received the dose distribution and the DVH of each plan. There were
paired comparisons of plans and one plan was defined as the reference,
which meant that every time the reference plan was a different one
depending on the comparison. They were asked to grade the quality of
the plan vis-à-vis the reference plan, on a five-level scale: clearly in-
ferior (-2), slightly inferior (-1), equal (0), slightly superior (1) or
clearly superior (2). They were not asked which criteria were used to
reach to the decisions.
The comparisons were evaluated with CGA, which was proposed as
a tool for quantitative treatment plan comparisons in Radiation
Therapy [13]. Similar to the Visual Grading Analysis used in radiology,
this method aims to include physical or biological measures used in
clinical practice (dose volume metrics such as DVH and dose statistics)
as well clinical judgments based on 3D dose distributions. The main
contribution of the method is the identification of clinically relevant
differences between plans. With CGA, the decision makers visually
evaluated the quality of the whole treatment plan and compared pairs
of plans presented side by side.
Each of the five comparison plans was analyzed, based on the results
of all comparisons and for all decision makers. The results for each
comparison plan were counted and the most answered value was
chosen for all the decision makers.
The statistical analysis was performed on the whole distribution of
answers (and not only on the most answered value) as follows. The
Kolmogorov–Smirnov test was used to examine if data were normally
distributed. The two groups of decision makers (ROs and MPs) were
compared using the Mann–Whitney U test. The Pearson Chi Square
(normally distributed data), or the Fisher’s exact test (non-normally
distributed data) was used to examine differences in the plan evalua-
tions between the two groups of decision makers. The significance level
(α) chosen was 5%.
At the end of the evaluation process of each case the decision ma-
kers were additionally shown the Pareto fronts (Figure S2 was pre-
sented alone without the dose distributions) and then asked to show the
position of their ideal plan on the Pareto front. The decision makers
were not allowed to see the plans again and they had to make their
decision with only the Pareto front they were shown.
3. Results
3.1. Clinical evaluation
Fig. 1 and Table 1 present the results of the most answered value for
each comparison plan for all the decision makers. For all five Pareto
fronts the plans with full PTV coverage (Plan 0_0 and 0) were
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considered equal, with plan 0 being more often preferred by the MPs
(30%) than by the ROs (17.8%) (p = 0.029). All the plans with PTV
under-dosage up to 5% were considered clearly superior to both plans
with full coverage (Plan 0 and Plan 0_0). However, there was a statis-
tically significant difference between the MPs and ROs as far as Plan 2.5
was concerned, with the MPs preferring it more often (p = 0.008 and
0.052 for Plan 0 and Plan 0_0 respectively). Plan 1 was considered in-
ferior compared to Plans 2.5 and 4, but the ROs tended to prefer the
Plans 2.5 and 4 more often than the MPs (p = 0.011 and p = 0.049,
respectively). Plan 5 was considered inferior compared to Plan 1 with
no statistically significant difference among the two groups of decision
makers. Plans 2.5 and 4 were considered equal for both the ROs and the
MPs. However, there was a statistically significant difference among the
two groups, with the ROs marginally evaluating Plan 4 as superior more
often than the MPs (p = 0.029). Plan 5 was considered inferior com-
pared to Plan 2.5, with the ROs considering it superior more often than
the MPs (p = 0.057). Plans 4 and 5 were considered equal for both
groups of decision makers.
For all cases, apart from Case 2, the plans in the central region of the
Pareto front (1–2.5% PTV under-dosage) received the best evaluations
both among both ROs and MPs. For cases 1, 3 and 4, the ROs tended to
prefer Plan 2.5 while the MPs preferred Plan 1 (p = 0.011). For Case 2,
with a large rectum-PTV overlap and for which the RTOG constraints
were not respected for all plans, there was a preference for the plans
with a lower rectum dose.
Fig. 1. Absolute evaluation of each of the five comparison plans on the Pareto front. The evaluation of a plan was summed over each comparison to obtain a total
value. The y-axis is the average value of the summed plan quality over all decision makers (all DM), all radiation oncologists (RO) or all medical physicists (MP).
Table 1
Plan evaluation on all five Pareto fronts among all the decision makers. The
value showed corresponds to the choice most often made. Plans on the vertical
column are evaluated compared to the reference plans on the horizontal line.
The test plan is considered: clearly inferior (-2), slightly inferior (-1), equal (0),
slightly superior (1) or clearly superior (2) to the reference plan. As an example,
Plan 1 is “clearly superior” to plan 0_0 and to plan 0.
Plan 0_0 0 1 2.5 4
0 =*, **
1 2 2
2.5 2* 2*, ** 1
4 2 2 1* =*
5 2 2 −1 −1* =
* indicates a statistically significant difference in the overall evaluations be-
tween ROs and MPs (accounting for the whole distribution of answers, see
statistical analysis in Supplementary Materials for more information).
** The RO results was 1.
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3.2. Choice of plan on the Pareto front
When the Pareto front for each case (except Case 2) was shown to
the decision makers, the majority (17 out of 19), chose a plan around
the region where the trade-off was more prominent (in most cases
around 0.5–1% PTV under-dosage). For Case 2 all the decision makers
chose plans in the region with the highest OAR sparing (4–5% PTV
under-dosage) even at the cost of poor PTV coverage.
4. Discussion
In this study, we present a new concept for a clinical evaluation of
treatment plans based on Pareto fronts in which we explored and re-
presented a clinically interesting trade-off. Our results were able to
define a clinically relevant area on the Pareto front, where plans were
also considered clinically equivalent.
The decision makers we consulted were free to compare the plans
based on their own criteria as long as the RTOG dose constraints for the
OARs were respected. In all cases but one (Case 2), all the plans offered
for evaluation were accepted according to the RTOG constraints for all
the organs at risk and the PTV. This means that plan evaluation was
indeed a question of clinical preference and judgment and not focused
on whether a plan was acceptable or not according to clinical con-
straints. In fact, the second case with 25% overlap between the PTV and
the rectum seemed to be an outlier, but we decided to include it because
such cases do exist in clinical practical and represent another type of
decision making situation.
CGA revealed an area on the Pareto front of the rectum sparing –
PTV under-dosage trade-off where plans were considered clinically
better for treatment. This area covered the 1 to 4% PTV under-dosage,
which means that the extreme regions of the front are removed.
Moreover, when data of Case 2 is removed, the region reduces even
further to 1–2.5%. Plans in this region were considered equal and
better/much better than the corresponding ones outside this region.
Plans sparing the rectum were considered clearly superior compared to
plans ensuring a good PTV coverage especially in the Pareto front re-
gion up to 1% PTV under-dosage. Overall, there was a consensus in
each of the two groups of decision makers regarding the preferred re-
gion, although the ROs tended to prefer more OAR sparing (regions
2.5–4% under-dosage) while the MPs preferred the 1–2.5% under-do-
sage region. In other words, the ROs more often preferred plans fa-
voring rectum sparing compared to plans with better PTV coverage,
while the MPs were more reluctant to sacrifice PTV coverage especially
in the region of more than 2.5% PTV under-dosage. That result corre-
sponds to previous studies [9,14].
Depending on the case and mainly on the PTV to rectum overlap
there were different decision strategies among the decision makers.
Both groups generally agreed in their evaluations for Case 2, for which
the overlap between the rectum and the PTV volume was large. For this
case, not all the plans on the Pareto front respected the RTOG con-
straints and, in particular, it wasn’t possible to reach full PTV coverage
without seriously compromising rectum sparing. In Cases 1, 3, 4 and 5,
for which the Pareto fronts have an L shape- binary pattern, the deci-
sion makers gave less homogenous evaluations, indicating different
clinical preferences..
2D Pareto front analysis of the values of specific decision objectives
can be used as a tool to provide the decision maker with additional
information on the possibilities available about a particular trade-off.
This raises the question of whether the decision maker will make si-
milar choices or use the same criteria if s/he is aware of the trade-off
values. Our results suggest that decision makers preferred another re-
gion when they recieved the additional information of the full solution
space concerning the specific trade-off. Interestingly, when the decision
makers were shown the Pareto fronts of each case at the end of the CGA,
their choice of the optimal plan was different than their evaluation with
CGA. While during plan comparisons they preferred a “balanced” plan
with a fair compromise on the main trade-off presented (in the 1 to 4%
under-dosage region), they made a different choice when they had a
visual insight on the shape of the trade-off through the Pareto front
(around 0.5% under-dosage region for all cases except for case 2). It
was evident, as most of them expressed, that further under-dosage on
the PTV led to a very low gain in rectum sparing. This access to addi-
tional information regarding the possibilities about a specific trade-off
could be particularly useful during decision making.
As far as we know, this is the first time that a clinical judgement has
been evaluated in terms of the inter-observer variability of trade-off
preference. Also, there are no studies related to a comparison of plans
lying on the Pareto front. Nevertheless, our findings that the ROs prefer
lower dose to OAR sparing over PTV coverage are in line with previous
studies on clinical judgement [9,14].
There are several limitations to our study which mainly arise from
the complexity of the optimization and the decision making processes.
They are described in the following paragraphs.
The number of cases used in this study is rather low (n = 5). This is
mainly due to the time needed to determine the Pareto fronts for each
case. However, that low number is balanced by the high number of
decision makers involved in the study. Our results (decision makers
prefer the 1 to 4% PTV under-dosage region, when not knowing the
Pareto front and the 0.5% PTV under-dosage region when knowing it)
may be biased by such a low number of cases. However, our main result
showing how the decision makers changed their mind when provided
with additional information about the Pareto front remains valid, no
matter whether the chosen region of the Pareto front is approximate or
not.4
Our method of manually creating Pareto optimal plans is burden-
some and time consuming, but it does enable us to obtain optimal plans.
It is also possible with systems generating automatic Pareto fronts, but
the quality of the resulting Pareto fronts should be assessed, because of
the approximations necessary during the optimization process [15]. It is
practically impossible to strictly control all the parameters of all the
structures involved at the same time. Therefore, keeping the values of
all other parameters of all OARs constant while allowing for dose de-
viations of, on average, 1 Gy maximum is the best that could be done
yet. Such variation might affect the decision making in specific cases,
but not to such an extent as to question our results. Additionally, we
cannot control or accurately investigate which parameters most af-
fected the decision makers. As far as decision making is concerned there
is a big unconscious component in the process which involves not only
reasoning but also visual inspection [16]. Our choice of a 1 Gy max-
imum dose deviation was an acceptable compromise easily handled
manually, but does emphasise the importance of keeping all other
parameters constant or within acceptable limits.
Complete optimization is a multi-dimensional problem that includes
several OARs (rectum, bladder, femoral heads)as well as other para-
meters such homogeneity, conformity, TCP and NTCP values. Our study
was limited to a two-dimensional Pareto front and we do not know
what would happen if an additional parameter would have been used
for trade-off (e.g. three-dimensional Pareto hyper-plan). The biggest
difficulty in deciding upon the best radiation treatment plan for each
patient is the lack of universally accepted criteria. The probabilities of
possible complications for each individual patient are not currently
known or predictable. Since planning criteria usually conflict in some
way, the decision largely depends on the preferences of the decision
maker, preferences that come from training, experience, and his/her
understanding of the patient’s clinical situation. In other words, an
evaluation based on a two-dimensional Pareto front is a clear limitation
of the whole picture.
In this study we have chosen the D50% as the evaluation parameter
for the rectum. During treatment plan evaluation in clinical practice,
the high dose region of the rectum DVH is what is usually considered.
Recently, the low to intermediate dose region is now also being taken
into consideration to account for late effects [17]. Large volumes at
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lower doses have been shown to correlate with several measures of late
rectal toxicity [18,19].
CGA of treatment plan evaluation shows the subjective preferences
of the decision makers. We explored clinical preferences of decision
makers from four radiotherapy treatment centers and our results reflect
the decision making strategies established in each center. Additionally,
they may reflect the experience of the decision makers.
The exploration of decision maker preferences provides insight in-
to clinically interesting areas of the solution space. Information of this
kind could prove valuable for automatic treatment plan selection.
Combining the Pareto optimality concept with auto planning does
provide not only a well optimized plan, based on the quality of the
other plans in the database, but an objectively optimal plan on the
Pareto front [20,21]. In addition, the mathematical definition of the
decision problem could include decision maker preferences in such a
way as to lead the search towards clinically preferred regions.
In conclusion, we assessed the inter-observer variability of decision
making using CGA as a tool and we defined a region where mathe-
matically equal plans were also considered clinically equal and pre-
ferred for treatment. We also noticed a difference in the region of
preference among the ROs and the MPs, with the ROs focusing more on
OAR dose sparing while the MPs favored ensuring PTV coverage. This
type of information could be valuable for planners and thus homo-
genize their practice in each center based on requirements established
by ROs and MPs.
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